PERSPECTIVES OF COOPERATION PHARMENA SA Pharmena was founded in - PowerPoint PPT Presentation

PERSPECTIVES OF COOPERATION

PHARMENA SA  Pharmena was founded in 2002 to develop & commercialize an active substance 1-methylnicotinamide  Headquartered in Lodz, Poland  Publicly traded on the Warsaw Stock Exchange (WAR:PHR)  Engaged in the discovery, development and market of innovative products for dermatological and other conditions  Dermatoligical areas of focus include alopecia (hair loss), inflammatory dermatoses, acne, burn healing as well as anti-wrinkle

RESEARCH & DEVELOPMENT  PHARMENA is focused on the search for innovative, unique solutions, which have resulted in numerous patent applications and granted patents  Involved in research on new medicines for the treatment of cardiovascular and other disorders based upon the proprietary active ingredient (1-MNA) used in its dermatological products  Established a dominant IP position for both topical and systemic uses of 1-MNA and owns the US IND and Canadian CTA regulatory filings

1-METHYLNICOTINAMIDE (1-MNA)  1-methylnicotinamide is previously unexplored metabolite of nicotinic acid and a catabolite of nicotinamide, which is one of the two main forms of the B-complex vitamin niacin (niacin = nicotinic acid and/or nicotinamide)  1-MNA is produced endogenously by the metabolism of dietary nicotinamide  1-MNA can also be obtained directly by consumption of various foods high in vitamin B3 (e.g., pork ham, wakame, and a variety of Japanese tea; Taguchi et al., 1986)  1-MNA provides significant anti-inflammatory and additional therapeutic benefits when administrated to the skin  The molecule is chemically stable and well tolerated by human organism

THREE BUSINESS LINES 1. COSMECEUTICALS  Portfolio of products with patent protection  World Market Value in 2012: 32 billion USD

THREE BUSINESS LINES 2. DIETARY SUPPLEMENT (NOVEL FOOD)  Innovative product based on 1-MNA – prevention of atherosclerosis (anti- inflamatory benefits)  European Market Value in 2011: around 500 MM USD (including only omega-3 products)

THREE BUSINESS LINES 3. DRUG DEVELOPMENT  Phase 2 Candidate, TRIA-662, Demonstrates Potential to Provide Benefits of Niacin Therapy without Flushing  TRIA-662 would address a $40 billion plus market including niacin, fenofibrate, statin and omega-3 fatty acid products

COSMECEUTICALS PRODUCTS

RESEARCH & DEVELOPMENT  Well diversified portfolio covering multiple indications as well as offering several differing formulations  The cosmeceutical products are sold exclusively through drug stores  All product’s safety & claims are supported by human trials involving over 1000 people

HAIR CARE PRODUCTS  A comprehensive approach to the problem of hair loss, eyebrow and eyelashes weakness and loss  Innovative solutions  Efficiency confirmed in dermatological trials  Broad product portfolio: shampoos, gels, conditioners, ampules, lotion, maskara and dietary suplement

SKIN CARE PRODUCTS

OPPORTUNITY HIGHLIGHTS #1  PHARMENA has a diversified topical portfolio covering multiple indications and in some cases including several formulations for an indication  PHARMENA ’s portfolio of dermocosmetics is currently generating nearly $5MM in revenue with products only marketed within Poland and rised by over 50% in 2013  Over The Counter (OTC) availability of product provides quick market entry for prospective partner

OPPORTUNITY HIGHLIGHTS #2  Uniqueness in the world scale – patented, natural, active substance 1-methylnicotinamide  Competitive price policy including volume discounts  Exclusive distribution rights  Fit a distributor requirements – individual packaging design available depended on local needs

THANK YOU FOR YOUR TIME